High- vs Intermediate-Dose Chemotherapy in Stage II/IIIa Breast Cancer
August 01, 2001
SAN FRANCISCO-Cancer and Leukemia Group B (CALGB) 9082 has failed in its second analysis to show a survival benefit for intensive therapy and transplant in primary breast cancer patients with multiple positive axillary lymph nodes. Nevertheless, outcomes in the 785-patient study, which compared high-dose and intermediate-dose consolidation chemotherapy with alkylating agents, are superior to outcomes achieved in studies of standard-dose therapy alone, William P. Peters, MD, PhD, said on behalf of investigators in the study, which was started more than 10 years ago. Dr. Peters, director of the Karmanos Cancer Institute, Detroit, spoke at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).